1. Rationally designed Human Cytomegalovirus gB nanoparticle vaccine with improved immunogenicity
- Author
-
Laurent Perez, Michela Perotti, Davide Demurtas, Jessica Marcandalli, Federica Sallusto, and Schleiss, Mark (ed.)
- Subjects
Human cytomegalovirus ,fusion ,Physiology ,Complement System ,Cytomegalovirus ,antibody-responses ,Pathology and Laboratory Medicine ,Antibodies, Viral ,Biochemistry ,Neutralization ,Cytomegalovirus Vaccines ,Mice ,Viral Envelope Proteins ,Immune Physiology ,Medicine and Health Sciences ,Nanotechnology ,Public and Occupational Health ,Enzyme-Linked Immunoassays ,Biology (General) ,GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries) ,risk ,0303 health sciences ,Mice, Inbred BALB C ,Immune System Proteins ,transplant recipients ,gh/gl ,biology ,Immunogenicity ,Vaccination and Immunization ,Titer ,Medical Microbiology ,Viral Pathogens ,Viruses ,Cytomegalovirus Infections ,Vaccines, Subunit ,Engineering and Technology ,Human Cytomegalovirus ,Female ,Antibody ,Pathogens ,Research Article ,Herpesviruses ,GeneralLiterature_INTRODUCTORYANDSURVEY ,QH301-705.5 ,Immunology ,Research and Analysis Methods ,Microbiology ,Antibodies ,03 medical and health sciences ,Antigen ,Virology ,Vaccine Development ,Genetics ,medicine ,Animals ,Humans ,antigenic domain 1 ,Antigens ,Immunoassays ,Molecular Biology ,Microbial Pathogens ,030304 developmental biology ,Ferritin ,030306 microbiology ,business.industry ,Organisms ,Biology and Life Sciences ,Proteins ,Protein Complexes ,gp116 ,RC581-607 ,medicine.disease ,Antibodies, Neutralizing ,infection ,Complement system ,Parasitology ,Immunization ,Immune System ,contains ,biology.protein ,Immunologic Techniques ,Nanoparticles ,Preventive Medicine ,Immunologic diseases. Allergy ,glycoprotein b ,business ,DNA viruses - Abstract
Human cytomegalovirus (HCMV) is the primary viral cause of congenital birth defects and causes significant morbidity and mortality in immune-suppressed transplant recipients. Despite considerable efforts in vaccine development, HCMV infection still represents an unmet clinical need. In recent phase II trials, a MF59-adjuvanted gB vaccine showed only modest efficacy in preventing infection. These findings might be attributed to low level of antibodies (Abs) with a neutralizing activity induced by this vaccine. Here, we analyzed the immunogenicity of each gB antigenic domain (AD) and demonstrated that domain I of gB (AD5) is the main target of HCMV neutralizing antibodies. Furthermore, we designed, characterized and evaluated immunogenic responses to two different nanoparticles displaying a trimeric AD5 antigen. We showed that mice immunization with nanoparticles induces sera neutralization titers up to 100-fold higher compared to those obtained with the gB extracellular domain (gBECD). Collectively, these results illustrate with a medically relevant example the advantages of using a general approach combining antigen discovery, protein engineering and scaffold presentation for modern development of subunit vaccines against complex pathogens., PLoS Pathogens, 16 (12), ISSN:1553-7374, ISSN:1553-7366
- Published
- 2020
- Full Text
- View/download PDF